US FDA places clinical hold on Regenxbio's gene therapy trials
28/01/2026 12:43
Jan 28 (Reuters) - Regenxbio RGNX.O said on Wednesday the U.S. Food and Drug Administration has placed a clinical hold on two of its experimental gene therapy programs for rare childhood diseases after a brain tumor was found in one treated patient. (Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Shailesh Kuber) ((Padmanabhan.Ananthan@thomsonreuters.com;))
Recent news on REGENXBIO
See all newsBrief: Regenxbio says Sarepta To Pay $39 Million To Regenxbio Within 10 Days Of Effective Date
Regenxbio climbs as new director buys nearly $1 million of stock
Brief: Regenxbio Strengthens Board Of Directors With Appointment Of Greg Ciongoli
U.S. STOCKS ON THE MOVE-Strategy, Ecovyst, Azenta
U.S. STOCKS ON THE MOVE-Azenta, Qiagen NV, Capricor Therapeutics